International Journal of Travel Medicine and Global Health

International Journal of Travel Medicine and Global Health

Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation

Document Type : Short Communication

Authors
Seyed Abbas Mirmalek 1
Fatemeh Elham Kani 1
Arianeb Mehrabi 2
Mehdi Chavoshi-Nejad 3
Seyed Alireza Salimi-Tabatabaee 4
Yekta Parsa 5
Soheila Yadollah-Damavandi 5
Tina Parsa 5
Amin Aidun 6, 7
1 Department of Surgery, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran
2 Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
3 Department of Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Students' Research Committee, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran
5 Young Researchers and Elite Club, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran
6 Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran
7 National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
10.20286/ijtmgh-030395
Abstract
Introduction: Overexpression of Human Epidermal Growth factor Receptor-2 (HER-2) is one of the most important prognostic and predictive factors of breast cancer, observed in 25% - 30% of breast carcinoma patients leading to poor prognosis and feasible anti HER-2 antibody drugs. The objective of this study was to evaluate the HER-2 frequency in target population and its correlation with histologic grade as well as tumor pathology, estrogen receptor (ER) and P53 in our patients.
Methods: A total of 300 cases (all female) aged 24- 80 year, were randomly selected from patients who were admitted in two of the Tehran University of Medical Sciences affiliated centers (Emam Khomeini Cancer Institute and Shariati hospital) over a 2-year period (2013-2014). Assessment of tumors for HER-2, P53, ER, pathological type and histologic grade was performed. HER-2 over expression defined as three plus (+++) in immunohistochemistry (IHC).
Results: The mean age was 49.6±11 years. HER-2 over expression was seen in 34% of the patients. Significant correlations were found between HER-2+, P53+ and high histologic grade and ER (P<0.05). However, there was no significant correlation between HER-2 and pathologic type of tumors in our study.
Conclusion: Co-expression of several poor prognostic biomarkers in breast cancer (HER-2 +, P53 +, ER- , high grade) may predict more aggressive phenotype, worse disease and lower overall survival in these patients.
Keywords
Breast carcinoma
Tumor Grading
Human Epidermal Growth Factor Receptor-2 (HER-2)
  1. Ban KA, Godellas CV. Epidemiology of Breast Cancer. Surg Oncol Clin N Am. 2014;23(3):409-422.
  2. Mirmalek SA, Elhamkani F, Tabatabaee SAS, Mahmoodzadeh H, Parsa Y, Yadollah-Damavandi S, et al. Introduction of HER-2 and a Short Review on Its Role in Prognosis and Treatment of Breast Cancer. GMJ. 2014;3(3):132-44.
  3. Brewster A, Helzlsouer K. Breast cancer epidemiology, prevention, and early detection. Curr Opin Oncol. 2001;13(6):420-5.
  4. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(2):122-92.
  5. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
  6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
  7. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012; 2012:743193.
  8. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652-4.
  9. Howell LP, Gandour-Edwards R, O'Sullivan D. Application of the Scarff-Bloom-Richardson tumor grading system to fine-needle aspirates of the breast. Am J Clin Pathol. 1994;101(3):262-5.
  10. Najmabadi KM, Azarkish F, Latifnejadroudsari R, Shandiz FH, Aledavood SA, Kermani AT, Esmaily HO. Self-disclosure of breast cancer diagnosis by Iranian women to friends and colleagues. Asian Pac J Cancer Prev. 2014;15(6):2879-82.
  11. Bell K. The breast-cancer-ization of cancer survivorship: implications for experiences of the disease. Soc Sci Med. 2014;110:56-63.
  12. Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res. 2012;72(18):4796-806.
  13. Chen HH, Su W-C, Guo H-R, Chang T-W, Lee W-Y. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan. Jpn J Clin Oncol. 2002;32(9):332-9.
  14. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. The breast. 2003;12(2):92-8.
  15. López‐Guerrero JA, Llombart‐Cussac A, Noguera R, Navarro S, Pellin A, Almenar S, et al. HER2 amplification in recurrent breast cancer following breast‐conserving therapy correlates with distant metastasis and poor survival. Int J Cancer. 2006;118(7):1743-9.
  16. Keyhani E, Muhammadnejad A, Karimlou M.Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran. Asian Pac J Cancer Prev. 2012;13(11):5477-82.

  • Receive Date 20 February 2015
  • Revise Date 06 April 2015
  • Accept Date 24 May 2015